The FDA approved Ionis Pharmaceuticals’ Dawnzera for preventing swelling attacks caused by the rare disease hereditary angioedema. A Takeda Pharmaceutical product dominates this market, but ...

At Epic’s annual Users Group Meeting, the EHR behemoth highlighted its growing AI strategy — announcing tools promising to benefit providers, payers and patients alike.

A clinically led, cross-functional team approach is essential during medical device integration projects to close data gaps, overcome common project pitfalls, complete optimal testing, and ensure ...

For decades, healthcare centered on physical locations – clinics, hospitals, examination rooms, and the like. If you needed treatment, you went to the care. Patients endured long waiting lines ...

Array Behavioral Care introduced a new model called Care Pathways, which aims to make mental health treatment more consistent and personalized while also improving patient outcomes.

Gilead Sciences, whose Kite subsidiary was one of the pioneers of ex vivo cancer cell therapy, is joining the pursuit of in vivo therapies with the acquisition of startup Interius BioTherapeutics ...

Digital health engagement app Wellth raised $36 million in Series C funding to expand its “daily care motivation platform,” ...

A combined bottom-up facility-level approach to integrated data and a top-down national-level effort for connected networks is needed to eliminate data silos and deliver frictionless care.

A coalition of 131 healthcare organizations is backing the Clinical Trial Modernization Act, which aims to expand patient access to clinical trials through financial support and other measures.

Saniona’s drug candidate could expand Jazz Pharmaceuticals portfolio in epilepsy. But this preclinical small molecule will need to show advantages in safety and efficacy to compete with Biohaven ...

GLP-1s have real value, but not all people respond to them the same way. The real question isn’t just what these drugs cost, but who they’re working for — and our healthcare system doesn’t ...